Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma

NCT04221516 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

52

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Carcinoma
Oligometastasis
Radiotherapy

Interventions

DRUG: Camrelizumab

Sponsor

Nanfang Hospital, Southern Medical University